Harbour BioMed closes Series C financing round

On July 10, Harbour BioMed announced completion of its Series C financing round of 102.8 million US dollars to accelerate the development of its innovative biopharmaceutical product pipeline targeting cancer, immunologic diseases, and COVID-19.

On July 10, Harbour BioMed announced completion of its Series C financing round of 102.8 million US dollars to accelerate the development of its innovative biopharmaceutical product pipeline targeting cancer, immunologic diseases, and COVID-19.

The round was led by Hudson Bay Capital, with participation from Country Garden VC, OrbiMed, GTJA Investment Group, Octagon Capital, Sage Partners, and existing investor Greater Bay Area Investment Fund.

The company closed a 75 million US dollars Series B+ round in March this year.

Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology, immunologic diseases, and COVID-19.

The company is building its proprietary pipeline through internal R&D programs, and diverse collaborations with partners.

Harbour BioMed leverages its two globally patented transgenic mouse platforms (Harbour Mice®) for generating fully human monoclonal antibodies, to develop innovative therapies for immuno-oncology, immunologic diseases.

In the meantime, Harbour BioMed also licenses the platforms to companies and academic institutions worldwide.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/15/harbour-biomed-closes-series-c-financing-round/.

Leave a Reply

Please Login to Comment